AR118056A2 - HISTONE DESACETILASE INHIBITOR FORMULATIONS IN COMBINATION WITH BENDAMUSTINE AND THE USE OF THE SAME - Google Patents
HISTONE DESACETILASE INHIBITOR FORMULATIONS IN COMBINATION WITH BENDAMUSTINE AND THE USE OF THE SAMEInfo
- Publication number
- AR118056A2 AR118056A2 ARP200100368A ARP200100368A AR118056A2 AR 118056 A2 AR118056 A2 AR 118056A2 AR P200100368 A ARP200100368 A AR P200100368A AR P200100368 A ARP200100368 A AR P200100368A AR 118056 A2 AR118056 A2 AR 118056A2
- Authority
- AR
- Argentina
- Prior art keywords
- bendamustine
- pharmaceutically acceptable
- combination
- acceptable salt
- histone
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 5
- 229960002707 bendamustine Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010033040 Histones Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen regímenes de dosificación, métodos de tratamiento, formulaciones de liberación controlada, y terapias de combinación que incluyen bendamustina, o una sal farmacéuticamente aceptable de las mismas y un inhibidor de HDAC, o una sal farmacéuticamente aceptable del mismo. Reivindicación 1: Una composición farmacéutica, caracterizada porque comprende bendamustina y un inhibidor de HDAC en donde la combinación es adecuada para administración separada, secuencial y/o simultánea. Reivindicación 2: Una composición farmacéutica en una forma de dosificación sólida adecuada para administración oral, la composición caracterizada porque comprende: un ingrediente activo que es el Compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo; un segundo ingrediente activo que es bendamustina o un éster, sal o solvato farmacéuticamente aceptable del mismo; y por lo menos un excipiente farmacéuticamente aceptable. Reivindicación 11: Un método para tratar o evitar un cáncer en un paciente, caracterizado porque comprende la etapa de administrar al paciente bendamustina y un inhibidor de histona desacetilasa (HDAC).Dosage regimens, treatment methods, controlled release formulations, and combination therapies including bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. Claim 1: A pharmaceutical composition, characterized in that it comprises bendamustine and an HDAC inhibitor wherein the combination is suitable for separate, sequential and / or simultaneous administration. Claim 2: A pharmaceutical composition in a solid dosage form suitable for oral administration, the composition characterized in that it comprises: an active ingredient which is the Compound of formula (1) or a pharmaceutically acceptable salt thereof; a second active ingredient which is bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof; and at least one pharmaceutically acceptable excipient. Claim 11: A method for treating or preventing cancer in a patient, characterized in that it comprises the step of administering bendamustine and a histone deacetylase inhibitor (HDAC) to the patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP200100368A AR118056A2 (en) | 2020-02-11 | 2020-02-11 | HISTONE DESACETILASE INHIBITOR FORMULATIONS IN COMBINATION WITH BENDAMUSTINE AND THE USE OF THE SAME |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP200100368A AR118056A2 (en) | 2020-02-11 | 2020-02-11 | HISTONE DESACETILASE INHIBITOR FORMULATIONS IN COMBINATION WITH BENDAMUSTINE AND THE USE OF THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118056A2 true AR118056A2 (en) | 2021-09-15 |
Family
ID=78076068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100368A AR118056A2 (en) | 2020-02-11 | 2020-02-11 | HISTONE DESACETILASE INHIBITOR FORMULATIONS IN COMBINATION WITH BENDAMUSTINE AND THE USE OF THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR118056A2 (en) |
-
2020
- 2020-02-11 AR ARP200100368A patent/AR118056A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20242299A1 (en) | GIP/GLP1 AGONIST COMPOSITIONS | |
| ES2553742T3 (en) | Pharmaceutical dosage form comprising 6'-fluor- (N-methyl- or N, N-dimethyl) -4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyran [3,4, b] indole] -4-amine | |
| EP3478283A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| MX2015017307A (en) | USE OF PRIDOPIDINE IN HIGH DOSE FOR THE TREATMENT OF HUNTINGTON'S DISEASE. | |
| AR085662A1 (en) | METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA | |
| BRPI0418026A (en) | phenylalanine derivatives or pharmaceutically acceptable salts thereof, pharmaceutical composition, alpha4 integrin antagonist, and therapeutic or preventative agent for diseases | |
| CL2019002172A1 (en) | Therapeutic agent for liver diseases. | |
| WO2021168483A3 (en) | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | |
| CL2024003616A1 (en) | Oral pharmaceutical composition and use for the therapy of progressive fibrosing interstitial lung diseases. | |
| CL2024003601A1 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases. | |
| EA202190544A1 (en) | APPLICATION OF RILUZOL TABLETS DISPOSING IN THE ORAL CAVITY FOR THE TREATMENT OF DISEASES | |
| AR037627A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DOSAGE FOR ORAL ADMINISTRATION AND USE OF THE PHARMACEUTICAL COMPOSITION AND OF A BASIC COMPONENT OF AN EFFECTIVE COUPLE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| HRP20240812T1 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| AR066666A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT | |
| MX2021003030A (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain. | |
| AR118056A2 (en) | HISTONE DESACETILASE INHIBITOR FORMULATIONS IN COMBINATION WITH BENDAMUSTINE AND THE USE OF THE SAME | |
| CO6270220A2 (en) | PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF A NON-STEROID ANTIINFLAMOTORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP DROPPED ARTHRITIS AND RELATED DISEASES | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN | |
| IL319025A (en) | Methods for the treatment or prophylaxis of endometriosis | |
| AR126393A1 (en) | COMBINED THERAPY FOR THE TREATMENT OF LIVER DISEASES | |
| CO2022001574A2 (en) | Synergistic combination of s-ketorolac and pregabalin in a pharmaceutical composition for the treatment of neuropathic pain. | |
| AR108793A1 (en) | COMPOSITIONS THAT INCLUDE TIMOLOL AND AN ANTI-INFLAMMATORY AGENT | |
| MX2025010198A (en) | High strength single unit dose formulations and methods of use thereof | |
| MX2024011932A (en) | Pharmaceutical combinations and methods of use of amino-pyrrolopyrimidinone compound | |
| AR132943A1 (en) | METHODS OF ADMINISTRATION OF A HEMOGLOBIN MODULATOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |